Schering-Plough Corporation (NYSE: SGP)’s NOXAFIL® (posaconazole) Oral Suspension has recently been approved by the USFDA for prophylaxis (prevention) of invasive Aspergillus and Candida infections in patients aged 13 and older who are at high risk of developing these infections due to being severely immunocompromised.
Immunocompromised or immunosuppressed individuals are hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. The said patient populations are more vulnerable to invasive fungal infections (IFIs), a leading cause of death in these high-risk populations.
The said approval turned NOXAFIL® into the first and only antifungal agent approved by the USFDA for the prevention of invasive fungal infections (IFIs) caused by Aspergillus species.
NOXAFIL® is a novel triazole antifungal agent discovered and developed by Schering-Plough Research Institute also currently under review by the European Medicines Agency (EMEA).
Read the full press release.
Comment Preview